Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastases Offers 60% Five-Year Overall Survival for Low-Volume Disease

Introduction: Cytoreductive surgery (CRS) with hyperthermic intraperitoneal early chemotherapy (HIPEC) has gained traction as a viable treatment option for patients with colorectal cancer peritoneal metastases (CRC-PM). Refinements have been made to patient selection and choice of HIPEC agent. We report outcomes with respect to peritoneal disease volume (peritoneal cancer index, PCI) and HIPEC agent for patients treated at the Western …